Tirofiban for Reduction of Thromboembolic Events in Endovascular Unruptured Aneurysm Repair

Inclusion Criteria: 1. Ages 18-80. 2. Participants with unruptured cerebral aneurysms eligible for stent-assisted coiling or flow diversion devices. 3. Completion of preoperative antiplatelet preparation. 4. Signed informed consent. Exclusion Criteria: 1. Abnormal platelet count (normal reference is 100-300×10\^9/L). 2. Allergy to study drugs and anesthetics. 3. Contradictory to MRI examination. 4. Known history of intracranial tumor, arteriovenous malformation, arteriovenous fistula, venous sinus thrombosis, hereditary cerebral small vessel disease, peripheral hemangioma (e.g., aortic aneurysm, limb vascular aneurysm). 5. Known history of cerebral parenchymal hemorrhage, subarachnoid hemorrhage, cerebral infarction, transient ischemic attack, or gastrointestinal bleeding within 6 months. 6. Clear indications for anticoagulation (presumed cardiac source of embolus, e.g., atrial fibrillation, prosthetic cardiac valves known or suspected endocarditis). 7. Antiplatelet drug (exclude aspirin and clopidogrel) being taken within 72 hours; anticoagulant drug (including heparin or oral anticoagulants) being taken within 10 days; 8. Participants with recurrent aneurysms who have received neurointerventional treatment. 9. Inability to follow endovascular procedures due to anatomical difficulties. 10. Severe renal (creatinine exceeding 1.5 times of the upper limit of normal range) or hepatic (ALT or AST \> twice the upper limit of normal range) insufficiency. 11. Severe heart failure (NYHA classes III and IV) or severe arrhythmias, including sick sinus syndrome, severe atrioventricular block, and bradycardia-related syncope. 12. Pregnant.